10 July 2020 - Single technology assessments published by NICE from April 2011 to October 2018 that evaluated cancer treatments were reviewed. 

Information regarding the use of real world evidence to directly inform the company-submitted cost-effectiveness analysis was extracted and categorised by topic. 

Materials for a total of 113 relevant single technology assessments were identified and analysed, of which nearly all (96%) included some form of real world evidence within the company-submitted cost-effectiveness analysis.

Read International Journal of Technology Assessment in Health Care article